News coverage about Zoetis (NYSE:ZTS) has been trending somewhat positive this week, Accern reports. Accern scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Zoetis earned a daily sentiment score of 0.13 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 46.4768988193003 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news articles that may have effected Accern Sentiment’s rankings:
- As Zoetis INC (ZTS) Shares Rose, Shareholder Johnson Investment Counsel INC Trimmed by $3.17 Million Its Holding – The Louisville Oracle (louisvilleoracle.com)
- Zoetis Inc. (ZTS) projected to achieve 32.40% earnings growth for this year – Wallstreet Investorplace (wallstreetinvestorplace.com)
- Roman Trawicki Sells 8,568 Shares of Zoetis Inc (ZTS) Stock (americanbankingnews.com)
- Zoetis Inc. (ZTS) Stock Unusual Activity – Wall Street Morning (wallstreetmorning.com)
- Zoetis Inc (ZTS) Receives Consensus Recommendation of “Buy” from Analysts (americanbankingnews.com)
A number of equities analysts have issued reports on ZTS shares. Zacks Investment Research lowered shares of Zoetis from a “hold” rating to a “sell” rating and set a $83.00 price target for the company. in a research report on Saturday, January 13th. Citigroup raised shares of Zoetis from a “neutral” rating to a “buy” rating and set a $85.00 price target for the company in a research report on Thursday, January 4th. BMO Capital Markets reissued a “hold” rating on shares of Zoetis in a research report on Monday, January 8th. Cowen set a $80.00 price target on shares of Zoetis and gave the stock a “buy” rating in a research report on Friday, November 17th. Finally, Morgan Stanley raised shares of Zoetis from an “equal weight” rating to an “overweight” rating and set a $80.00 price target for the company in a research report on Wednesday, November 29th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $80.28.
Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 15th. The company reported $0.69 EPS for the quarter, topping the consensus estimate of $0.66 by $0.03. The company had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.40 billion. Zoetis had a net margin of 16.28% and a return on equity of 65.96%. The firm’s revenue was up 14.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.47 EPS. research analysts predict that Zoetis will post 3.04 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, June 1st. Investors of record on Friday, April 20th will be issued a $0.126 dividend. This represents a $0.50 annualized dividend and a yield of 0.60%. The ex-dividend date of this dividend is Thursday, April 19th. Zoetis’s payout ratio is presently 28.57%.
In related news, EVP Roxanne Lagano sold 35,663 shares of the business’s stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $81.02, for a total value of $2,889,416.26. Following the completion of the sale, the executive vice president now owns 49,919 shares of the company’s stock, valued at approximately $4,044,437.38. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Heidi C. Chen sold 37,453 shares of Zoetis stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $81.02, for a total transaction of $3,034,442.06. The disclosure for this sale can be found here. In the last three months, insiders sold 105,569 shares of company stock valued at $8,594,429. 0.31% of the stock is owned by insiders.
COPYRIGHT VIOLATION WARNING: This story was reported by BBNS and is the sole property of of BBNS. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://baseballnewssource.com/2018/03/14/zoetis-zts-earning-somewhat-positive-press-coverage-report-shows/1926955.html.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.